Adams Catherine Owen - 18 Jun 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Director
Issuer ticker: AGIO
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 17:21:19 UTC
Prior SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as attorney-in-fact for Catherine Owen

Key filing fact

Adams Catherine Owen filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 23 Jun 2026.

Key facts

This page summarizes Adams Catherine Owen's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 17:21.

Change

Previous filing in this sequence was filed on 16 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816838 Primary reporting owner

Owen Adams Catherine

Relationship: Director
Address: C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE
Signature: /s/ William Cook, as attorney-in-fact for Catherine Owen
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Options Exercise

Transaction value
Shares: +2,816
Change %: +35%
Price: $0.000000^*
Shares after: 10,865
Date: 18 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
Shares: -2,816
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 2,816
Exercise price
Footnotes: F1, F2

AGIO transaction Derivative

Restricted stock units

Award

Transaction value
Shares: +2,927
Change %
Price: $0.000000^*
Shares after: 2,927
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 2,927
Exercise price
Footnotes: F1, F3

AGIO transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +14,950
Change %
Price: $0.000000^*
Shares after: 14,950
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 14,950
Exercise price: $34.16
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F2

The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Footnote F3

The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Footnote F4

These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.